Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Lilly’s new approach to cholesterol. Eli Lilly’s experimental cholesterol drug doubled patients’ HDL (Opens in a new window), or good cholesterol, setting the stage for a race between the ...

Eli Lilly (LLY) shares rallied 14.3% in the last trading session to close at $839.96. ... Merck's consensus EPS estimate for the upcoming report has changed -4% over the past month to $2.16.

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

A cautious culture cost Novo its obesity lead. Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly.

Eli Lilly has just achieved something no other pure-play pharmaceutical company can boast: ... The next largest U.S. pharma company is Merck, with a market value of around $300 billion, ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company. The company’s shares closed yesterday at $81.37. Don’t Miss TipRanks ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss. ...